Ensuring Universal Access to COVID-19 Diagnosis, Treatment and Prevention
TAG and the Center for Economic and Social Rights produced this joint publication, as part of CESR’s COVID-19 “Recovering Rights” series of briefs.
Treatment Action Group Statement on New HIV Remission Case Report at AIDS2020
Yesterday, a widely reported presentation by Ricardo Diaz at the ongoing virtual International AIDS Conference (AIDS2020) disclosed that one out of 30 total participants in an HIV cure-related research trial conducted in Brazil has not experienced an HIV viral load rebound for a little over a year (64.7 weeks) after interrupting antiretroviral therapy (ART).
Treatment Action Group Statement on Bedaquiline Unaffordability
Treatment Action Group welcomes the Global Drug Facility / Stop TB Partnership's negotiation of what amounts to a 32% savings on bedaquiline, the backbone of improved, all-oral regimens for treating drug-resistant TB.
Treatment Action Group and the PrEP4All Collaboration Respond to Reported Remdesivir Results for COVID-19
Treatment Action Group (TAG) and the PrEP4All Collaboration welcome results from randomized controlled trials of therapies for COVID-19, but are seriously concerned about claims that data from a National Institutes of Allergy and Infectious Diseases (NIAID) study of the Gilead drug remdesivir...
An Activist’s Guide to Rifapentine for the Treatment of TB Infection
The English version of this publication updated 2024. Please refer to the earlier versions on this page if you need languages other than English. English version updated April 2020. The updated guide reflects new information from recently completed clinical…
TAG Statement on WHO Updated TB Preventive Therapy Guidance
Last week, Treatment Action Group was pleased to receive the World Health Organization’s (WHO) update to its guidance on TB preventive therapy (TPT).
Treatment Action Group Statement on HIV Treatments and SARS-CoV-2/COVID-19
Treatment Action Group (TAG) is urging caution regarding the use of antiretroviral (ART) drugs as treatments for SARS-CoV-2/COVID-19. While there is clearly an acute need to carefully and quickly study interventions that may have activity against SARS-CoV-2, the virus which causes COVID-19 disease, it’s vitally important to be aware of the information that is currently available.
Isoniazid/Rifapentine (3HP) Access Roadmap and Patent Landscape
Our publication, Isoniazid/Rifapentine (3HP) Access Roadmap and Patent Landscape, provides a landscape of patent applications filed by the French pharmaceutical company Sanofi on combinations of two essential medicines used to prevent tuberculosis (TB): isoniazid and rifapentine.
African Declaration to Eliminate Hepatitis C and Improve the Health of People Who Use Drugs
A group of organizations that includes Treatment Action Group issued this statement/declaration today, while attending INHSU 2020 Africa: the 1st Regional Conference on Hepatitis Care in Substance Users.
Responding to Difficult-to-Treat HCV Subtypes Prevalent in Sub-Saharan Africa
An issue brief that discusses the recent discovery of HCV subtypes that show resistance to direct-acting antiretroviral (DAA) regimens that are responsive to treatments in people expressing the 1a/1b subtype.